Carbamazepine diminishes the sensitivity of the plasma arginine vasopressin response to osmotic stimulation.
Carbamazepine, a drug used to treat manic-depressive illness, has been reported to possess antidiuretic properties, but its effects on arginine vasopressin (AVP) secretion are controversial. Consequently, we examined plasma AVP secretion during hypertonic (5%) saline infusion in seven manic-depressive patients while on placebo and after 3-5 weeks of carbamazepine treatment. We also measured carbamazepine's effects on basal levels of the hormone in cerebrospinal fluid. Carbamazepine significantly reduced the sensitivity of the plasma AVP response to osmotic stimulation without affecting the osmotic threshold for AVP secretion. Moreover, carbamazepine did not affect baseline weight, plasma osmolality, plasma sodium, urine output, plasma AVP, or cerebrospinal fluid AVP. Although the functional significance of these findings remain to be fully determined, the fact that carbamazepine significantly reduced AVP secretion without inducing diuresis supports previous suggestions that carbamazepine enhances renal responsivity to available AVP. In addition, since carbamazepine failed to affect the osmotic threshold, the reported cases of carbamazepine-induced inappropriate AVP secretion and water intoxication must be very uncommon and probably represent idiosyncratic responses.
D001127:Arginine Vasopressin / Q000097:blood* / Q000134:cerebrospinal fluid; D001714:Bipolar Disorder / Q000097:blood* / Q000188:drug therapy; D001769:Blood; D002220:Carbamazepine / Q000494:pharmacology* / Q000627:therapeutic use; D004231:Diuresis / Q000187:drug effects; D006801:Humans; D009994:Osmolar Concentration; D012462:Saline Solution, Hypertonic; D012964:Sodium / Q000652:urine; D012965:Sodium Chloride
D012462:Saline Solution, Hypertonic; D001127:Arginine Vasopressin; D002220:Carbamazepine; D012965:Sodium Chloride; D012964:Sodium